Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prurigo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Prurigo. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-000410-38 Sponsor Protocol Number: LP0066-1019 Start Date*: 2013-10-25
    Sponsor Name:LEO Pharma A/S
    Full Title: Topical Aprepitant in Prurigo Patients (iTAPP) An exploratory phase IIa trial with topically applied aprepitant in patients with prurigo
    Medical condition: Prurigo can present either with hyperkeratotic nodules as prurigo nodularis or without nodules as Prurigo simplex. The disease is characterised by intensely pruritic, lichenified, or excoriated pap...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006329-23 Sponsor Protocol Number: INCB54707-206 Start Date*: 2022-05-05
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004739-22 Sponsor Protocol Number: DER-201805 Start Date*: 2021-03-16
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: Efficacy of ruxolitinib cream in Prurigo nodularis patients: A randomized, placebo-controlled pilot study (PRUX)
    Medical condition: Patients with symptomatic Prurigo nodularis with active skin manifestations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037084 Prurigo nodularis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002818-13 Sponsor Protocol Number: DEALSZ-2021-001 Start Date*: 2023-05-12
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...
    Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005602-31 Sponsor Protocol Number: mec 06/239 Start Date*: 2006-10-24
    Sponsor Name:Academic Medical Center
    Full Title: Excimer laser versus clobetason propionaat in prurigo form of atopic dermatitis
    Medical condition: the excimer laser appears to be a promising treatment for localized atopic dermatitis. Therefore we designed a randomized trial to investigate the efficacy of this excimer laser versus topical clob...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005638-10 Sponsor Protocol Number: SST-Pr-2-2005 Start Date*: 2007-02-12
    Sponsor Name:University of Münster
    Full Title: Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease
    Medical condition: Prurigo nodularis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004198-38 Sponsor Protocol Number: KPL-716-C201 Start Date*: Information not available in EudraCT
    Sponsor Name:Kiniksa Pharmaceuticals, Ltd.
    Full Title: KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects wit...
    Medical condition: Pruritus in Subjects with Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed) BE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001715-36 Sponsor Protocol Number: RD.03.SPR.115828 Start Date*: 2017-10-23
    Sponsor Name:GALDERMA R&D, SNC
    Full Title: A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)
    Medical condition: Prurigo nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005024-42 Sponsor Protocol Number: TCP-102 Start Date*: 2014-06-18
    Sponsor Name:Menlo Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis
    Medical condition: Pruritus nodularis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004294-13 Sponsor Protocol Number: RD.06.SPR.202699 Start Date*: 2020-10-05
    Sponsor Name:Galderma S.A.
    Full Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003928-32 Sponsor Protocol Number: RD.06.SPR.203890 Start Date*: 2021-11-29
    Sponsor Name:Galderma S.A.
    Full Title: A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004293-25 Sponsor Protocol Number: RD.06.SPR.202685 Start Date*: 2020-06-25
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) HU (Completed) AT (Completed) DK (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001219-53 Sponsor Protocol Number: TR11 Start Date*: 2019-03-06
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRI...
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001601-85 Sponsor Protocol Number: UKM10_0037 Start Date*: 2014-02-14
    Sponsor Name:University Hospital Münster
    Full Title: Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial
    Medical condition: Patients with generalized chronic pruritus (> 6 weeks duration) and showing prurigo nodularis refractory to pretreatment with antihistamines (normal dosage, four weeks)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10037084 Prurigo nodularis LLT
    17.0 100000004858 10018123 Generalized pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004789-17 Sponsor Protocol Number: RD.06.SPR.203065 Start Date*: 2020-07-08
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001505-17 Sponsor Protocol Number: BILA-3716/PRU Start Date*: 2016-07-29
    Sponsor Name:FAES FARMA, S.A.
    Full Title: An exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases.
    Medical condition: Chronic spontaneous urticaria and the following skin disorders: 1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermat...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10012435 Dermatitis and eczema HLT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-003018-29 Sponsor Protocol Number: 2016-003018-29 Start Date*: 2017-05-31
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Apremilast as anti-pruritic treatment in patients with prurigo nodularis
    Medical condition: Prurigo nodularis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004210-25 Sponsor Protocol Number: MTI-106 Start Date*: 2018-06-04
    Sponsor Name:Menlo Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
    Medical condition: Pruritus in adults with prurigo nodularis (PN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003801-90 Sponsor Protocol Number: EFC16460 Start Date*: 2020-02-11
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlle...
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10029263 Neurodermatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) PT (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005627-17 Sponsor Protocol Number: TR03 Start Date*: 2015-12-01
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:59:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA